{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Triple-Negative+Breast+Cancer+%28TNBC%29&page=4", "query": { "condition": "Triple-Negative Breast Cancer (TNBC)", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 243, "total_pages": 25, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Triple-Negative+Breast+Cancer+%28TNBC%29&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Triple-Negative+Breast+Cancer+%28TNBC%29&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T21:44:23.881Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02900664", "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma" ], "interventions": [ { "name": "PDR001", "type": "BIOLOGICAL" }, { "name": "ACZ885", "type": "BIOLOGICAL" }, { "name": "CJM112", "type": "BIOLOGICAL" }, { "name": "TMT212", "type": "DRUG" }, { "name": "EGF816", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 283, "start_date": "2016-08-23", "completion_date": "2021-03-17", "has_results": false, "last_update_posted_date": "2022-03-29", "last_synced_at": "2026-10-10T21:44:23.881Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Nashville, Tennessee + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02900664" }, { "nct_id": "NCT03184558", "title": "Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Triple Negative Breast Cancer", "Inflammatory Breast Cancer Stage IV" ], "interventions": [ { "name": "Bemcentinib; pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BerGenBio ASA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2017-07-26", "completion_date": "2018-08-20", "has_results": true, "last_update_posted_date": "2021-11-09", "last_synced_at": "2026-10-10T21:44:23.881Z", "location_count": 5, "location_summary": "Duarte, California • San Diego, California • Kansas City, Missouri + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03184558" }, { "nct_id": "NCT05107674", "title": "A Study of NX-1607 in Adults With Advanced Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer, Epithelial", "Gastric Cancer", "GastroEsophageal Junction (GEJ) Cancer", "Head and Neck Squamous Cell Carcinoma", "Metastatic or Unresectable Melanoma", "Non-small Cell Lung Cancer (NSCLC)", "Metastatic Castration-resistant Prostate Cancer (mCRPC)", "Malignant Pleural Mesothelioma (MPM)", "Triple Negative Breast Cancer (TNBC)", "Metastatic Urothelial Carcinoma", "Cervical Cancer", "Diffuse Large B Cell Lymphoma (DLBCL)", "Richter Transformation", "Microsatellite Stable Colorectal Carcinoma" ], "interventions": [ { "name": "NX-1607", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nurix Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 345, "start_date": "2021-09-29", "completion_date": "2028-02-28", "has_results": false, "last_update_posted_date": "2025-09-09", "last_synced_at": "2026-10-10T21:44:23.881Z", "location_count": 10, "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05107674" }, { "nct_id": "NCT02032277", "title": "A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "FEMALE", "summary": "18 Years to 99 Years · Female only" }, "enrollment_count": 634, "start_date": "2014-04-02", "completion_date": "2020-11-12", "has_results": false, "last_update_posted_date": "2021-01-20", "last_synced_at": "2026-10-10T21:44:23.881Z", "location_count": 61, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 47 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Salinas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02032277" }, { "nct_id": "NCT02393794", "title": "Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Triple-Negative Breast Cancer", "Breast Cancer" ], "interventions": [ { "name": "Romidepsin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Priyanka Sharma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 51, "start_date": "2015-07-17", "completion_date": "2026-07", "has_results": false, "last_update_posted_date": "2025-10-06", "last_synced_at": "2026-10-10T21:44:23.881Z", "location_count": 7, "location_summary": "Fairway, Kansas • Kansas City, Kansas • Overland Park, Kansas + 3 more", "locations": [ { "city": "Fairway", "state": "Kansas" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02393794" }, { "nct_id": "NCT05113966", "title": "Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Trilaciclib", "type": "DRUG" }, { "name": "Sacituzumab Govitecan-hziy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "G1 Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-12-08", "completion_date": "2024-06-13", "has_results": true, "last_update_posted_date": "2025-01-29", "last_synced_at": "2026-10-10T21:44:23.881Z", "location_count": 22, "location_summary": "Chandler, Arizona • Bakersfield, California • Los Angeles, California + 18 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05113966" }, { "nct_id": "NCT05490472", "title": "JAB-2485 Activity in Adult Patients With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors", "ER+ Breast Cancer", "Triple Negative Breast Cancer, TNBC", "ARID1A Gene Mutation", "Small Cell Lung Cancer, SCLC" ], "interventions": [ { "name": "JAB-2485 (Aurora A inhibitor)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jacobio Pharmaceuticals Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2022-12-20", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-01-09", "last_synced_at": "2026-10-10T21:44:23.881Z", "location_count": 4, "location_summary": "Detroit, Michigan • St Louis, Missouri • Dallas, Texas + 1 more", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Dallas", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05490472" }, { "nct_id": "NCT06324240", "title": "Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage IA Breast Cancer AJCC v8", "Anatomic Stage IB Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Early Stage Triple-Negative Breast Carcinoma", "Locally Advanced Triple-Negative Breast Carcinoma", "Metastatic Triple-Negative Breast Carcinoma", "Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage IA Breast Cancer AJCC v8", "Prognostic Stage IB Breast Cancer AJCC v8", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8", "Recurrent Breast Carcinoma", "Unresectable Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Vaccine Therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2025-12-02", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-01-26", "last_synced_at": "2026-10-10T21:44:23.881Z", "location_count": 4, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06324240" }, { "nct_id": "NCT07555210", "title": "Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer (Triple Negative Breast Cancer (TNBC))", "Renal Cell Carcinoma (Kidney Cancer)", "Melanoma (Skin Cancer)", "Non-Small Cell Lung Cancer", "MSI-H/dMMR Rectal Cancer", "Squamous Cell Carcinoma Mouth", "Invasive Mammary Carcinoma", "Classic Hodgkin Lymphoma" ], "interventions": [ { "name": "Dual-Energy X-ray Absorptiometry (DXA)", "type": "DEVICE" }, { "name": "High Resolution peripheral Quantitative Computed Tomography (HRpQCT)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Jessica Mezzanotte Sharpe", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2025-08-25", "completion_date": "2028-07-01", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-10T21:44:23.881Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07555210" }, { "nct_id": "NCT01307891", "title": "Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Triple Negative Breast Cancer", "Stage IV Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "Abraxane alone", "type": "DRUG" }, { "name": "Abraxane + Tigatuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2011-03", "completion_date": "2017-06", "has_results": true, "last_update_posted_date": "2017-10-26", "last_synced_at": "2026-10-10T21:44:23.881Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01307891" } ] }